CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.
Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .
Resultado final
Expand the current Danish Sentinel Surveillance System to include blood samples from individuals with respiratory viral infections of concern, in order to “live monitor” emerging viral variants and investigate novel host-pathogen interactions.Create a prospective cohort based on the Spanish Sentinel Surveillance System to include blood samplesfrom individuals with respiratory viral infections of concern, in order to “live monitor” emerging viral variants and investigate novel host-pathogen interactions.
A repository of HNE-patient derived organoids from European and black South African individuals available for the entire scientific community (se abrirá en una nueva ventana)A repository of HNE-patient derived organoids from European and black South African individuals available for the entire scientific communityGeneration of REACT organoid platform
Create a large biobank prospective collection for WP 04 - WP 07 (se abrirá en una nueva ventana)Collection of a large prospective biobank including live cells from hospitalized patients infected with SARS-CoV-2, influenza, or RSV. For the latter, this will also include sampling from children admitted to hospitals in RegH. Collection of a large prospective biobank including live cells from hospitalized patients infected with SARSCoV-2, influenza, or RSV from the nodes of the ISCIII-BBP coordinated by CNIO Biobank.
A plan describing activities of dissemination and exploitation of results.The utility of results through dissemination and exploitation will be planned according to the plan provided in section 2.2.1 in Part B of Annex 1.
Lung Chip (se abrirá en una nueva ventana)Task 12.1. Lung-chip generation; M21-M27. Taking advantage of current protocols forlung tumor-chip generation within the widening partner, lung-chip models will be established from resected tumor-free lung tissue. Characterization will be performed by immunofluorescence and FACS (lineage and functional markers for T/ B cells, macrophages, endothelial cells, epithelial cells and fibroblasts, among others).
Identify the most critical parameters for immune protection against SARS-CoV2 within the T cell compartments (se abrirá en una nueva ventana)Characterisation of T cell immunity in SARS-CoV. In-depth evaluation of CD4 and CD8 T cell immune responses to SARS-CoV-2 infection, including epitope landscape, cross-reactivity, HLA-specific effects, TCR usage, T cell functional and transcriptomic profiling, cytokine secreting profiles.
Data Management Plan (se abrirá en una nueva ventana)The Data Manager will create a Data Management Plan (DMP), which will aim to maximise access to and re-use of research data gathered and produced through REACT where possible.The DMP will be reviewed and updated regularly during the project. This will be done in close collaboration with the Ethics Manager (EM).
Online meeting with existing EU projects to initiate collaboration (se abrirá en una nueva ventana)Collaborate with existing initiatives such as the EU-funded ORCHESTRA project and the European COVID-19 Data Platform. Build on existing collaborations and platforms such as GISAID, ELIXIR, ICPerMed and 1+ Million Genomes Initiative.
Suggest measures to improve the critical immune parameters in susceptible individuals (se abrirá en una nueva ventana)In-depth evaluation of T cell immunity will be assessed directly in patients ‘at risk’ of severe disease, i.e.with various immune deficiencies, either induced by disease or medication (e.g. hematological B cell malignancies, MS (or other) patients treated with antiCD20 (rituximab, ocrelizumab or ofatumumab), patients with T cell malignancies, other immunosuppressive drugs (e.g. patients under transplantation). This will allow us to determine, in real patient cohorts, how deficiencies in different components of the immune system will influence the overall antiviral response, the balance of the immune reaction and the capacity to control disease. We aim to evaluate a total number of 60 patients, representing a minimum of three different types of immune deficiencies.
Risk and Contingency Plan (se abrirá en una nueva ventana)The PC will carefully observe any potential conflicts and risks related to both scientific delivery and the participants’ contractual obligations. Any conflict will be dealt with immediately and with the appropriate measures. With the assistance of the legal team at SSI, the coordinator will negotiate a Consortium Agreement (CA) with all participants prior to project start. This will ensure that all the participants are aware of their rights and obligations as well as processes for conflict resolution. The project’s identified risks will be monitored carefully, and if any issues should occur, these will be dealt with in a timely and efficient manner, taking all necessary precautions and steps to mitigate the risks. Moreover, the initial contingency plan will be updated annually by the Scientific Core Group, comprised of all WP leaders to ensure that it remains relevant and useful.
Create a grand overview of existing resources (se abrirá en una nueva ventana)Integrate existing cohorts, collections and biobanks from the consortium partners. Denmark: RegH, Zealco, DTU and SSI cohorts, and the Danish National Biobank. Sweden: Karolinska cohorts. Spain: ISCIII-BBP coordinated by CNIO Biobank. As lead partner in this WP we will revise and harmonize all the cohorts samples and research information so as to integrate and share with participants from other WPs as required. The biorepository of biological samples from black South African hospitalized patients will be stored at the NICD; samples will be shipped as required to participants from other WPs.
A repository of longitudinal plasma/serum, whole blood, swab, PBMCs and neutrophils from SARS-CoV-2 infected hospitalized black South African individuals with and without HIV-1 infection (se abrirá en una nueva ventana)A repository of longitudinal plasma/serum, whole blood, swab, PBMCs and neutrophils from black South African individuals with and without HIV-1 infection (from Dec 2020 through different SARS-CoV-2 waves, dominated by specific viral variants (wave 1: ancestral D614G, wave 2: beta, wave 3: delta, and is ongoing). Recruitment complete; clinical data analysis, patient sample selection for D 7.2-7.4 (M12).
Data Management updated version (se abrirá en una nueva ventana)The Data Manager will create a Data Management Plan (DMP), which will aim to maximise access to and re-use of research data gathered and produced through REACT where possible.The DMP will be reviewed and updated regularly during the project. This will be done in close collaboration with the Ethics Manager (EM).
We will prepare materials including (1) Project logo and a graphical chart to build the consortium signature and increase REACT visibility worldwide. (2) Slide templates edited with the project chart will be distributed to all partners. (3) A brochure and poster presenting the partners, the consortium, its objectives and expected results, contact and website details will be issued to support the dissemination activities of the project to the wider public (M3).
Project website and REACT materials (logo, templates and brochure) (se abrirá en una nueva ventana)It will include the proposed innovations and knowledge to reach their final exploitation and, thus, make them available and delivered to the scientific community and to the society. The web site will count with a secure intranet system to have internal communications among REACT project members (M3).
Ensure approvals and legal aspects of the use of already genotyped cohorts for this study.
Publicaciones
Autores:
Garreta E, Moya-Rull D, Stanifer ML, Monteil V, Prado P, Marco A, Tarantino C, Gallo M, Jonsson G, Hagelkruys A, Mirazimi A, Boulant S, Penninger JM, Montserrat N.
Publicado en:
Star Protoc, 2022, ISSN 2666-1667
Editor:
Cell Press, [2020]
DOI:
10.1016/j.xpro.2022.101872
Autores:
Zarina Nauryzgaliyeva, Iphigénie Goux Corredera,Elena Garreta, and Nuria Montserrat*
Publicado en:
Front Cell Dev Biol., 2023, ISSN 2296-634X
Editor:
Frontiers Media Sa
DOI:
10.3389/fcell.2023.1273923
Autores:
Garreta E; Prado P; Stanifer ML; Monteil V; Marco A; Ullate-Agote A; Moya-Rull D; Vilas-Zornoza A; Tarantino C; Romero JP; Jonsson G; Oria R; Leopoldi A; Hagelkruys A; Gallo M; González F; Domingo-Pedrol P; Gavaldà A; Del Pozo CH; Hasan Ali O; Ventura-Agu
Publicado en:
Cell Metabolism, 2022, ISSN 1550-4131
Editor:
Cell Press
DOI:
10.1016/j.cmet.2022.04.009
Autores:
Safi W; Marco A; Moya D; Prado P; Garreta E; Montserrat N
Publicado en:
Frontiers In Cell And Developmental Biology, 2022, ISSN 2296-634X
Editor:
Frontiers Media Sa
DOI:
10.3389/fcell.2022.948395
Autores:
Goux Corredera, Iphigénie; Amato, Gaia; Moya-Rull, Daniel; Garreta, Elena; Montserrat, Nuria
Publicado en:
Kidney International, 2025, ISSN 0922-3444
Editor:
Elsevier
DOI:
10.1016/j.kint.2025.01.043
Autores:
Anisha Pahuja 1, Iphigénie Goux Corredera 1, Daniel Moya-Rull Elena Garreta , Nuria Montserrat
Publicado en:
Curr Opin Cell Biol ., 2024, ISSN 0955-0674
Editor:
Curr Opin Cell Biol .
DOI:
10.1016/j.ceb.2023.102306
Autores:
Garreta, Elena; Moya‐Rull, Daniel; Marco, Andrés; Amato, Gaia; Ullate‐Agote, Asier; Tarantino, Carolina; Gallo, Maria; Esporrín‐Ubieto, David; Centeno, Alberto; Vilas‐Zornoza, Amaia; Mestre, Rafael; Kalil, María; Gorroñogoitia, Izar; Zaldua, Ane Miren; Sanchez, Samuel; Izquierdo Reyes, Laura; Fernández‐Santos, María Eugenia; Prosper, Felipe; Montserrat, Nuria
Publicado en:
Advanced Materials, 2024, ISSN 1613-6810
Editor:
Wiley - V C H Verlag GmbbH & Co.
DOI:
10.1002/ADMA.202400306
Buscando datos de OpenAIRE...
Se ha producido un error en la búsqueda de datos de OpenAIRE
No hay resultados disponibles